Celularity Inc. announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma Inc. (now part of Gilead Sciences Inc.), Amgen Inc., and Genentech Inc. (now part of Roche Holdings Inc.). Ms. Parksjoins the Celularity Board of Directors with more than 30 years of commercial experience in the pharmaceutical and biotechnology industries.

Most recently, she served as Senior Vice President, Head of U.S.Commercial for Kite Pharma Inc. (acquired by Gilead Sciences Inc. for $11.9 billion), where she developed and executed the strategic plan for the commerciallaunch of Yescarta®, the first CAR-T therapy approved for large B-cell lymphoma. Previously, Ms. Parks served as Vice President, Head of Global Marketing for Pharmacyclics Inc. (acquired by AbbVie Inc. for $21 billion), where she was responsible for the marketing strategy and launch of Imbruvica®. Before that, she served as Vice President, Sales for Amgen Inc., where she successfully led the Hospital and Nephrology sales teams. In addition, she served as Senior Vice President, Specialty Biotherapeutics and Managed Care for Genentech Inc. (acquired by Roche Holdings Inc. for $46.8 billion).

She currently serves on the boards of Calliditas Therapeutics AB, CTI BioPharma Corp., Kura Oncology Inc., Soligenix Inc. and TriSalus Life Sciences and the Lymphoma Research Foundation. Ms. Parks earned an MBA from Georgia State University and a BS from Kansas State University. On May 31, 2022, Jay R. Bloom, a Class I member of the board of directors of Celularity Inc. and a member of the board's audit committee, notified the board of directors of his intention to resign as a member of the board and all committees thereof effective June 1, 2022.

Mr. Bloom's decision to resign was not due to any disagreement with Celularity on any matter, or relating to its operations, policies, or practices. The board appointed John Sculley to serve on the audit committee of the board, effective June 2, 2022. On June 2, 2022, upon recommendation of the nominating and corporate governance committee of the board, the board appointed Ms. Diane Parks as a Class I director to fill the vacancy left by the resignation of Mr. Bloom, to serve until her successor is elected and qualified, or, if earlier, until her death, disability, resignation, disqualification or removal.

Ms. Parks was not selected by the board to serve as a director pursuant to any arrangement or understanding with any person.